BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 18711180)

  • 1. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.
    Donovan MJ; Hamann S; Clayton M; Khan FM; Sapir M; Bayer-Zubek V; Fernandez G; Mesa-Tejada R; Teverovskiy M; Reuter VE; Scardino PT; Cordon-Cardo C
    J Clin Oncol; 2008 Aug; 26(24):3923-9. PubMed ID: 18711180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized prediction of tumor response and cancer progression on prostate needle biopsy.
    Donovan MJ; Khan FM; Fernandez G; Mesa-Tejada R; Sapir M; Zubek VB; Powell D; Fogarasi S; Vengrenyuk Y; Teverovskiy M; Segal MR; Karnes RJ; Gaffey TA; Busch C; Haggman M; Hlavcak P; Freedland SJ; Vollmer RT; Albertsen P; Costa J; Cordon-Cardo C
    J Urol; 2009 Jul; 182(1):125-32. PubMed ID: 19450827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved prediction of prostate cancer recurrence through systems pathology.
    Cordon-Cardo C; Kotsianti A; Verbel DA; Teverovskiy M; Capodieci P; Hamann S; Jeffers Y; Clayton M; Elkhettabi F; Khan FM; Sapir M; Bayer-Zubek V; Vengrenyuk Y; Fogarsi S; Saidi O; Reuter VE; Scher HI; Kattan MW; Bianco FJ; Wheeler TM; Ayala GE; Scardino PT; Donovan MJ
    J Clin Invest; 2007 Jul; 117(7):1876-83. PubMed ID: 17557117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.
    Donovan MJ; Osman I; Khan FM; Vengrenyuk Y; Capodieci P; Koscuiszka M; Anand A; Cordon-Cardo C; Costa J; Scher HI
    BJU Int; 2010 Feb; 105(4):462-7. PubMed ID: 19624594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
    Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
    Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
    Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
    BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
    Henshall SM; Quinn DI; Lee CS; Head DR; Golovsky D; Brenner PC; Delprado W; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2001 Jan; 61(2):423-7. PubMed ID: 11212224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Jayachandran J; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Stephenson AJ; Freedland SJ
    BJU Int; 2009 Nov; 104(10):1452-6. PubMed ID: 19466946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
    Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    Mizuno R; Nakashima J; Mukai M; Okita H; Kosugi M; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M
    BJU Int; 2009 Nov; 104(9):1215-8. PubMed ID: 19389009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
    Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF
    Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
    Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
    J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.
    Shariat SF; Walz J; Roehrborn CG; Zlotta AR; Perrotte P; Suardi N; Saad F; Karakiewicz PI
    J Clin Oncol; 2008 Mar; 26(9):1526-31. PubMed ID: 18349404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
    Rampersaud EN; Sun L; Moul JW; Madden J; Freedland SJ
    J Urol; 2008 Aug; 180(2):571-6; discussion 576. PubMed ID: 18554662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.